Allyson J. Ocean, M.D., Joins Novocure Board of Directors
Novocure (NASDAQ: NVCR) announced the election of Dr. Allyson J. Ocean to its Board of Directors. Dr. Ocean is a prominent medical oncologist with expertise in gastrointestinal oncology, currently serving at Weill Cornell Medicine. Her role is expected to enhance Novocure’s mission to extend survival in aggressive cancers through innovative therapies. She is also co-founder of a non-profit focused on pancreatic cancer treatment access. Novocure is known for its Tumor Treating Fields, a revolutionary therapy approved for conditions such as glioblastoma and malignant pleural mesothelioma, with ongoing studies in various cancers.
- Dr. Ocean's election brings extensive expertise in gastrointestinal oncology, which may enhance strategic direction.
- Her involvement could lead to improved insights and guidance in developing effective cancer therapies.
- Concerns may arise regarding continuity and potential experience gaps on the Board as new members join.
ROOT,
“We are honored to welcome
“I look forward to working with the esteemed individuals on Novocure’s board to advance our mission to help patients who currently have limited treatment options,”
About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Headquartered in Root,
Forward-Looking Statements
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on
View source version on businesswire.com: https://www.businesswire.com/news/home/20230223005180/en/
Investors:
investorinfo@novocure.com
610-723-7427
Media:
media@novocure.com
610-723-7428
Source: Novocure
FAQ
Who is Dr. Allyson Ocean and what role will she play at Novocure?
What impact does Dr. Ocean's election have on Novocure's strategy?